Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

Posted byZacks Equity Research Leave a comment on Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

Editas’ (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

Leave a comment

Your email address will not be published. Required fields are marked *